“…In an animal model of spontaneously developing diabetes, 4-PBA was able to normalize end-diastolic elastance, helping to alleviate a common comorbidity of diabetes (Takada et al, 2012). In contrast, 4-PBA administration did not reduce aortic ER stress nor atherosclerotic lesions in a streptozotocin-induced diabetes model (Kurokawa et al, 2009). However, 4-PBA was able to prevent streptozotocininduced diabetic nephropathy, with reduced kidney hypertrophy, reduced glomerular mesangial cell proliferation, alleviated mesangial matrix accumulation, and decreased hydroxyproline levels (Luo et al, 2010).…”